乳腺癌NM23-H1基因蛋白表达与肿瘤淋巴结转移的关系  

RELATIONSHIP BETWEEN NM23-H1 GENE EXPRESSION AND LYMPH NODE METASTASIS IN HUMAN BREAST CANCER

作　　者：张丽萍[1] 许良中[1] 朱伟萍[1] 

机构地区：[1]上海医科大学肿瘤医院病理科

出　　处：《上海医科大学学报》1998年第6期412-415,共4页Journal of Fudan University(Medical Science)

摘　　要：研究乳腺癌肿瘤组织中ＮＭ２３－Ｈ１基因蛋白表达，探讨该基因的蛋白表达水平与肿瘤腋下淋巴结转移、肿瘤直径、血管密度以及雌激素受体状况等多项临床病理指标之间的关系。方法应用ＮＭ２３－Ｈ１单克隆抗体以及第８因子相关抗原多克隆抗体免疫组织化学酶标ＡＢＣ法对６０例乳腺癌组织、２０例乳腺纤维腺瘤及２０例癌旁正常乳腺组织中的肿瘤转移抑制基因蛋白产物以及肿瘤新生血管进行了标记。结果ＮＭ２３－Ｈ１蛋白在正常乳腺组织以及乳腺纤维腺瘤的导管上皮中均有高水平表达，乳腺癌肿瘤组织中ＮＭ２３－Ｈ１基因存在较高频率的表达（８８．３％），但表达水平存在差异：高水平表达百分率为４８．３％（２９／６０），低水平表达百分率为５１．６％（３１／６０），腋下淋巴结转移阳性组病例高水平表达率为１２．９％（４／３１），腋下淋巴结转移阴性组病例则为８６．２％（２５／２９）。ＮＭ２３－Ｈ１基因表达水平，腋下淋巴结转移阴性组显著高于腋下淋巴结转移阳性组（Ｐ＜０．０１），并且该基因在肿瘤直径大于２ｃｍ，新生血管密度高于平均值组常呈低水平表达，而不同年龄，雌激素受体状况以及不同病理类型之间该基因的表达水平无差异（Ｐ＞０．０５）。结论ＮＭ２３－Ｈ１基因在控制乳腺癌?PURPOSE To investigate NM23-H1 gene expression in breast cancer tissue and its relations to some clinical pathological parameters including axillary lymph node metastasis, estrogen receptor status, tumor size and angiogenesis density. METHODS The expression of NM23-H1 gene and tumor angiogenesis density were detected in 60 cases of breast cancer with ABC immunohistochemical method using monoclonal antibody for NM23-H1 protein and polyclonal antibody for F8. RESULTS Of the 60 patients examined, 53 (88.3%) had NM23-H1 gene expression and the expression levels were different. Twenty nine of that 60 cases (48.3%) showed high level of expression and 31( 51.6%) low level or no expression. The high expression rete was 12.9% (4/31) in axilary lymph node metastasis group and 86.2% (25/29) in the group without lymph node metastasis. The expression level of NM23-H1 gene in these two groups was different, being statistically significant ( P <0.01). The expression level was related to the tumor diemeter and angiogenesis density but was not related to the patient's age, estrogen receptor status and pathological subtype ( P >0.05). CONCLUSIONS NM23-H1 gene may play an important role in the control of the metastasis of human breast cancer.

关 键 词：乳腺癌 NM23-H1基因 淋巴结转移 基因表达 

分 类 号：R737.902[医药卫生—肿瘤]